The Diagnostic Imaging MRI modality focus page provides information, videos, podcasts, and the latest news about industry product developments, trial results, screening guidelines, and protocol guidance that touch on the use of MRI across the healthcare continuum, including breast, neurological, cardiovascular, prostate imaging, and more.
March 31st 2025
LI-RADS category 5 (LR-5) assessment had an 11 percent higher AUC for detecting hepatocellular carcinoma (HCC) in patients with non-cirrhotic chronic hepatitis C (CHC) in comparison to those with cirrhotic CHC.
Community Practice Connections™: The 2nd Annual Hawaii Lung Cancers Conference®
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Cases & Conversations™: Expert Perspectives on Leveraging Recent Advances to Transform SCLC Treatment
April 4, 2025 | New York, NY & Virtual
Register Now!
Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®
View More
Medical Crossfire®: How Can Thoracic Teams Facilitate Optimized Care of Patients With Stage I-III EGFR Mutation-Positive NSCLC?
View More
Lung Cancer Tumor Board®: How Do Emerging Data for ICIs, BiTEs, ADCs, and Targeted Strategies Address Unmet Needs in the Therapeutic Continuum for SCLC?
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
2025 International Symposium of Gastrointestinal Oncology (ISGIO)
September 12-13, 2025
Register Now!
Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection
View More
(CME Credit Only) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure
View More
(MOC and CME Credit) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure
View More
(CME Credit Only) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment
View More
(MOC and CME Credit) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment
View More
43rd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 12-14, 2025
Register Now!
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
43rd Annual Miami Breast Cancer Conference®
March 5-8, 2026
Register Now!
Can MRI-Based AI Enhance Pre-Op Prediction of Tumor Deposits in Patients with Rectal Cancer?
October 31st 2024For patients with rectal cancer, an emerging nomogram that combines deep learning and clinical factors had greater than 16 percent and 23 percent increases in accuracy and specificity, respectively, for pre-op prediction of tumor deposits in comparison to clinical factors alone.
Artifact Reduction Drives Technology Advances with Updated Version of Echelon Synergy MRI System
October 30th 2024Emerging technologies included with the 10th version of the 1.5T MRI platform include Synergy DLR Clear and Synergy Vision that are geared toward mitigating common challenges with artifacts.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
Enhancing Lesions on Breast MRI: Can an Updated Kaiser Scoring Model Improve Detection?
September 26th 2024The addition of parameters such as patient age, MIP sign and associated imaging features to the Kaiser score demonstrated a 95.6 percent AUC for breast cancer detection of enhancing lesions on breast MRI in recently published research.
MRI or Ultrasound for Evaluating Pelvic Endometriosis?: Seven Takeaways from a New Literature Review
September 13th 2024While noting the strength of MRI for complete staging of disease and ultrasound’s ability to provide local disease characterization, the authors of a new literature review suggest the two modalities offer comparable results for diagnosing pelvic endometriosis.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Diffusion-Weighted MRI and Neoadjuvant Chemotherapy for Rectal Cancer: What New Research Reveals
September 3rd 2024In a comparison of imaging assessments to gauge the effectiveness of neoadjuvant chemotherapy for rectal adenocarcinoma, researchers found the combination of diffusion-weighted imaging and MR tumor regression grading had a 90 percent area under the curve (AUC) and a negative predictive value (NPV) of 93 percent.